6-Phosphofructo-2-kinase (EC 2.7.1.105)/ fructose-2,6-bis-phosphatase (EC 3.1.3.46) catalyzes the synthesis and degradation of fructose 2,6-bisphosphate, a ubiquitous stimulator of glycolysis. The liver (L-type) and muscle
(M-type) mRNAs for this bifunctional enzyme arise from distinct promoters of the same gene. We have now characterized in rat hepatoma FT02B cells another mRNA, which is transcribed from a third promoter of that gene. This F-type mRNA is present in fetal rat liver and muscle, in rat placenta, and in several established rat cell lines. The F promoter contains no TATA box but contains several binding sites for Spl and for members of the ets oncogene family. Transfection of FT02B cells with constructs containing the intact or mutagenized F promoter showed that its activity depends mainly on one of these sites. This site bound a heteromeric FT02B cell protein indistinguishable from the ets-related GA binding protein a/ankyrin-repeats GA binding protein j3 transcription factor.
In many types of transformed cells the glycolytic flux is abnormally high, even in aerobiosis (1) . This situation may involve fructose 2,6-bisphosphate, a potent stimulator of 6-phosphofructo-1-kinase (2) . The synthesis and degradation offructose 2,6-bisphosphate are catalyzed by the bifunctional enzyme 6-phosphofructo-2-kinase (PFK-2)(ATP: D-fructose-6-phosphate 2-phosphotransferase, EC 2.7.1.105)/fructose-2,6-bisphosphatase (FBPase-2) (D-fructose-2,6-bisphosphate 2-phosphohydrolase, EC 3.1.3.46) . There are several PFK-2/FBPase-2 isozymes that differ in tissue distribution and control by protein kinases (3) . We have cloned a 55-kb gene (gene A) that encodes the liver (L-type) and muscle (M-type) isozymes through use of different promoters (4) . The L-type (2.1 kb) and M-type (1.9 kb) mRNAs share 13 consecutive exons. The 5' end of each mRNA consists of an additional coding exon, which is specific for the M (exon lM) or for the L (exon 1L) isozyme (5) . In the gene, exon 1L lies 4.3 kb downstream from exon lM (Fig. 1A) . Thus, isozyme M has the same sequence as isozyme L, except for the N terminus where the first 32 residues of isozyme L are replaced by an unrelated nonapeptide. As a result, isozyme M is not controlled by cAMP-dependent protein kinase which, in isozyme L, phosphorylates Ser-32, thereby activating FBPase-2 and inactivating Rat hepatoma PFK-2/FBPase-2 differs from isozyme L (7, 8) . The mRNA from the FT02B hepatoma cell line hybridizes The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. with a probe specific for exon lM but does not hybridize with a probe specific for exon L, and yet it is 0.3 kb longer than the M-type mRNA (8). We have now cloned from FT02B cells a PFK-2/FBPase-2 mRNA that we call F-type. § It arises from gene A through use of a third promoter located 1.5 kb upstream from exon lM. This F promoter has unique features when compared with the M and L promoters and is controlled by transcription factors of the ets family.
MATERIALS AND METHODS
Construction, PCR Amplification, and Screening of the FT02B cDNA Library. Total RNA was extracted (9) from FTO2B cells (6) exposed for 12 hr to 1 ,uM dexamethasone (8) . Poly(A)-rich RNA (10) was used to construct a cDNA library in AZAPII (Stratagene). PCR was done with Taq DNA polymerase and buffers from Boehringer Mannheim on 1.7 x 107 phages heated at 70°C for 10 min, using primers at 0. 6-1.8 ug/ml and 30-40 cycles of 1 min at 50°C, then at 72°C, then at 95°C followed by a step of 10 min at 72°C. PCR products were ligated in a T-vector prepared from pBluescript (11) . To screen the library, plaques (4 x 106 phages) were replicated on Hybond-C-extra (Amersham) membranes prehybridized for 4 hr at 65°C in 6x standard saline/citrate (SSC) (12)/5x Denhardt's solution (12)/0.5% SDS/10 mM sodium phosphate, pH 6.9/1 mM EDTA. Hybridization with the Megaprime (Amersham)-labeled (3.105 cpm/ml) 1.4-kb 22cl cDNA probe (5) lasted for 16 hr at 65°C in the same solution containing herring sperm DNA at 100 p,g/ml and the probe denatured for 5 min at 100°C. The membranes were washed three times (5 min, room temperature) in 2x SSC/0.1% SDS and once (60 min, 65°C) in 0.5 x SSC/0. 1% SDS. pBluescript phagemids, obtained according to Stratagene from the selected AZAP phages, were used for sequencing with Sequenase (United States Biochemical) and with T3 and T7 primers and oligonucleotides (oligos) made by Pharmacia.
DNA and RNA Analysis. For Southern blotting (12) oligo G ( Fig. 1B) ug of total RNA or with 2 ug of poly(A)-rich RNA extracted directly from frozen tissues with the Dynabeads system (Dynal, Oslo) and mixed with 20 pg of yeast tRNA. The incubation was treated for 30 min at 30°C with RNase Ti (1.2-2.5 Mg/ml) and RNase A (20-40 ug/ml), and the digestion products were analyzed on a 6% acrylamide sequencing gel.
Plasmids, Site-Directed Mutagenesis, and Oligos. The Hph I-Taq I and BamHI-Taq I fragments (Fig. 1B ) were cloned in pXP2 (6) upstream from the firefly luciferase reporter gene. Site-directed mutagenesis was done (Amersham Mutagenesis system version 2) on the BamHI-Taq I fragment cloned in M13mp8, with the following antisense oligos in which the underlined nucleotides of the ets motifs had been modified as indicated: 5'-GAAACGCGAGACCAAGGCGGGGAAC (proximal motif), 5'-CCAGCTCACTTGCiGGGCG-GCAATG (central motif), and 5'-GCCTAAGCTTGGiTT-TGGGAATCG (distal motif). Double-stranded oligos B and C were described (6) , and oligo D was as shown in Fig. 1B , with cohesive Xba I ends (CTAGA) added. Oligos Dmutets and DmutSpl, with the nucleotides underlined modified as indicated, were 5 '-CTAGACCCAAACCAAGCTTAG-GCGGGCAAA and 5'-CTAGACCCAAAGGAAGCTTAG-IATGGCAAA. Oligo ets was ATAACCAGGAAGTGGGC with 5'-end Ava I-Xho I sites and a 3'-end Ava I site. Oligo etsmut was oligo ets with the central GG replaced by CC. Oligo Spl was from Promega. The single-stranded oligos E, F, and G are shown in Fig. 1B .
Cell Transfection and Gel-Shift Assays. FT02B cells were transfected (6) , with pSV2CAT as internal control. Luciferase and chloramphenicol acetyltransferase were assayed with the Promega and Boehringer Mannheim kits, respectively. Gel shifts were done (6) (4) . This fact and hybridization data (8) suggested that the F-type mRNA has specific 5' terminal exon(s) spliced with exon lM. The putative F-type-specific 5' end was searched for in the FT02B cDNA library by PCR between the T3 primer of AZAP and first oligo E, then oligo F (Fig. 1B ). This procedure yielded products that hybridized by Southern blotting with oligo G, which were then cloned in pBluescript. These clones shared the same sequence from the 3' end of the insert. Four of them extended upstream of exon lM. The longest clone contained an exon lM lacking the first 15 bp but preceded by 100 nt found 842 bp upstream in gene A, themselves preceded by 13 nt found 510 bp more upstream in the gene (Fig. 1B ). An RNA probe containing the first 113 nt on the 5' side of the PCR product revealed, on RNA blots of FT02B RNA, a 2.2-kb band which increased in intensity, as expected (8), in cells treated with dexamethasone (data not shown). Thus, FT02B mRNA derives from gene A; it contains at least two exons that are not found in the M-type or L-type mRNA and are spliced with an alternative acceptor site in exon lM (Fig. 1B) .
To obtain the full sequence of the mRNA, we screened the cDNA library with a cDNA probe (exons 3-14 of gene A) known to hybridize with FT02B mRNA (8). Ten positive clones out of 4 x 106 recombinant clones were found. One clone contained a cDNA that extended from the poly(A) tail to include not only the PCR product but also 139 additional bp on the 5' side. The other clones were incomplete, with a 5' end located in exon lM or downstream from it. In gene A, the additional sequence of the longest clone is in direct continuation with that of the PCR product. To determine whether this cDNA was a full-length copy of the FT02B mRNA, RNase protection was performed with an RNA probe corresponding to the BamHI-Nhe I fragment (Fig. 1B) , which extends 219 nt upstream from the cDNA. Five protected bands were observed with transcription initiation sites Proc. Nati. Acad. Sci. USA 90 (1993) located, within 120 bp, upstream and downstream from the 5' end of the cDNA (Fig. 1B) . The presence of multiple initiation sites was consistent with the promoter structure (see below). The sequence of the F-type mRNA was established from the longest clone. This sequence was identical to that of the M-type mRNA (5) , except for the deletion of 15 nt at the 5' end of exon lM and for the addition of two exons, termed exons laF and lbF, upstream from the truncated exon lM (Fig.  1A) . When compared with the length of the M-type mRNAi.e., 1708 nt excluding the poly(A) tail-the length of the F-type mRNA (2010 nt) was consistent with the difference of 0.3 kb seen between these two mRNAs by Northern blotting (8).
To determine tissue distribution of F-type mRNA, RNase protection was done with an RNA probe specific for this mRNA (Fig. 2) . The mRNA was present in hepatoma, fibroblast, and myoblast cell lines. Its concentration decreased upon differentiation of L6 myoblasts into myocytes (Fig. 2) and in Rat-i fibroblasts made quiescent by lowering serum concentration in the culture from 10 to 0.1% (data not shown). F-type mRNA concentration increased in FTO2B cells upon dexamethasone treatment, as expected (8). This mRNA was found in the two fetal tissues examined-namely, liver and muscle-and in lung and thymus. This mRNA was present at much lower levels or was undetectable in the other adult tissues tested. The highest concentration was in preterm placenta, with a decrease at term. Thus, expression of the F-type mRNA appears to correlate with cell proliferation.
Translation of the M-type mRNA starts in exon lM (21). In the F-type mRNA, there is one AUG upstream from this exon, but a stop codon is encountered eight triplets downstream. Therefore, exons laF and lbF are noncoding, and the sequence of the protein translated from this mRNA is not expected to differ from that of isozyme M. Several other genes have distinct promoters that function in a stageor tissue-specific manner and give rise to different mRNAs with the same coding sequence but different 5' leaders (22) . Our identification of the 5' end of the F-type mRNA allowed characterization of the F promoter.
Characterization of F Promoter. A construct containing the BamHI-Taq I genomic fragment (Fig. 1B) upstream from a promoterless luciferase reporter gene was transfected in FTO2B cells. This fragment behaved as a promoter: luciferase activity was stimulated 100to 1000-fold the background (Fig. 3 , construct a versus construct k). The 150 bp upstream from the 5' end of the cDNA contain no TATA box but contain six Spl consensus (23) sequences (Fig. 1B) ; this is typical of TATA-less promoters, in which multiple cap Fig. IB ) was cloned upstream from the promoterless luciferase (Luc) reporter gene and transfected in FT02B cells. Thin bars are pXP2 polylinker sequences. Circles and triangles refer to the ets and Spl motifs, respectively. Consensus on the sense strand are shown by symbols above the line; consensus on the antisense strand are shown by symbols below the line. Filled circles refer to ets motifs destroyed by site-directed mutagenesis. Relative activities are ratios of luciferase activity of the test plasmid to chloramphenicol acetyltransferase activity of the cotransfected control plasmid, normalized for activity ofthe nonmutated promoter at 100; for the latter, absolute luciferase activity values ranged from 6,000 to 50,000 units. Data are means ± SEM for four or five independent experiments, except for constructs i and j (two experiments). sites exist (24), as found here. This region also contains three binding motifs for transcription factors of the ets oncogene family (25, 26) , which includes at least 12 members that share a conserved DNA-binding domain. Some of them are tissue- (6); L6, rat myogenic cell line (6) ; d, days of gestation; dex, dexamethasone (1 AM for 12 hr). The 149-nt RNA probe contained the last 13 nt of exon laF plus 100 nt of exon lbF and pBluescript polylinker sequences. Because the probe contained one PCR-generated mismatch located 20 nt from the 3' end, protected fragments of 117 and 97 nt were expected. Protected fragments of 105 nt could correspond to unspliced transcripts. ns, Nonspecific (see tRNA control lane). To assess the contribution ofthese ets X activity, we changed to CC the core specifically contact ets family members; their binding to DNA (26, 28, 29) . Fig. 3 sl distal (construct b) or of the proximal (co had no effect, whereas loss of both (cor promoter activity by 15-20%. In contras central ets motif (construct c) decreased l 75%, an effect not strengthened by the either one (constructs f or g) or of the tw( ets sites. About a third of the residual act mutant was ascribed to the two Spl sites I from the proximal ets site. Indeed, the Hi fragment (construct i), which binds oi extracts (6) , displayed <10% of the ac promoter. Addition to this fragment of cluster (oligo B) failed to restore prom expected level (construct j versus e), sl cis-acting sequences, such as the Spl mr proximal and/or distal ets/Spl clusters, promoter activity. In any case, the centrn for most activity ofthe F promoter. This r with our findings (6) that the protein(s) sj the HindIII-Hph I fragment (Fig. 1B) interact(s) exclusively with the central e only DNase I footprint seen with such e) promoter (BamHI-Taq I fragment) corre Factor Binding to F Promoter. This b gated by performing gel shifts with oligos the three ets/Spl clusters. Oligo B, whici central ctuster, produced with FT02B e: shifts (bands a-d) that were inhibited b affinity binding site for Etsl and other family, but not by oligo etsmut (Fig. 4 , la did not compete (lane 11). Lack of bin extracts was not from hindrance by ti because recombinant Spl alone did not b not shown). Oligo C, which corresponi cluster, did not compete either (lane 10). I with FIT02B extracts a specific shift thk oligo Spl, and it bound recombinant Sp (lanes 5, 6, 9, 15, 16) indi mune serum. The quantity of GABP proteins M for lane 12 as for lanes 13-16. Arrows a-d, nonspecific; F, free probe. [8] [9] [10] [11] E to representative independent experiments. involved in the cell Oligo D, which corresponds to the distal cluster, produced with FTO2B extracts a specific shift that was inhibited by motifs to F promoter oligo Spl and by oligo Dmutets but was not inhibited by oligo GG residues that DmutSpl or oligo ets, and it bound recombinant Spl. The and are essential for affinity of oligo D for Spl was much lower than that of oligo hows that loss of the C (data not shown). Thus, in FTO2B extracts, the distal and instruct d) ets motifs proximal ets/Spl clusters of the promoter bind Spl, whereas istruct e) decreased the central cluster binds ets-related proteins. This result is ;t, destruction of the consistent (28-30) with our finding (6) that FTO2B protein promoter activity by binding to this motif is prevented by in vitro methylation of concomitant loss of the GG core on the sense strand and of an adenosine located D other (construct h) 4 bp downstream on the antisense strand. ivity of the triple ets
The association of Spl and ets motifs in the F promoter was located downstream reminiscent of that found in the long terminal repeat of the ph I-Taq I promoter human T-cell leukemia virus 1. There, Spl stimulates DNA nly Spl in FTO2B binding of, and transactivation by, Etsl (18). We found by gel -tivity of the intact shift that oligo B could bind purified Etsl, but this association the central ets/Spl was not modified by purified Spl (data not shown). Moreoter activity to the over, the central ets motif of the F promoter (present in oligo aggesting that other B) was not involved in a cooperation with the neighboring iotifs present in the Spl motifs because its presence stimulated the activity of the also contribute to F Hph I-Taq I promoter fragment (Fig. 3 , construct i) to the al ets site accounted same extent when it was associated with these Spl motifs esult was consistent (construct h versus e) as when it was not so associated pecifically bound by (construct i versus j).
in FTO2B extracts
To identify the ets-related proteins present in FTO2B cells, ets site and that the gel shifts of oligo B were performed with FTO2B extracts and ctracts on the whole antibodies that recognize Etsl and Ets2. These antibodies did isponds to this site. not prevent or retard the complexes seen with oligo B (Fig.  minding was investi-4, lane 9), excluding a role of Etsl or Ets2 in these complexes. s matching (Fig. 1B) FTO2B proteins were therefore separated by SDS/PAGE, h corresponds to the and fractions were renatured to determine their ability to bind xtracts four specific oligo B. A fraction containing proteins with Mr of 45,000y oligo ets, a high-50,000 produced shifts that comigrated with complexes a, b, members of the ets and c (data not shown), suggesting the involvement of an nes [1] [2] [3] [4] . Oligo Spl oligomeric protein with subunits present in the same fraction. (Fig. 4, lane 5) .
B -<-t<-
Anti-GABPP antibodies inhibited complexes a and b but did not inhibit complex c (lane 6), suggesting that complex c represented binding of the GABPa monomer to oligo B and Vo that complexes a and b were due to binding of GABPa//3 heteromers. This hypothesis was confirmed with recombi--* it -nant GABPa and -,3, which produced shifts that comigrated with complexes a, b, and c (lane 12). These shifts were prevented by oligo B and by anti-GABPa antibodies, whereas only the two upper shifts were prevented by anti-GABP,B antibodies (lanes 13-16) .
The binding specificity of the ets family members depends on the DNA sequences flanking the ets motif (26, 32) and on their protein partner (33). Thus, if GABP is the FTO2B factor that binds to the F promoter, the relative affinity of the 12 13 14 15 16 FTO2B proteins for the three ets/Spl clusters of the F promoter should be the same as that of GABP. This was the ion (olago B, Flg. 1B) case, as oligos D and C did not prevent the complexes in absence (lanes 1, 8, obtained with oligo ets, whereas oligo B did prevent these ) ng) (lanes 2, 3, 4, iii, complexes -G7---I'-------'. ---1r "and icated. n.im., Nonim-complexes ( Fig. 5) . Therefore, the main complexes (a, b, and vas five times as much c) formed between FT02B proteins and the central motif of ,specific shifts; n.s., the F promoter are contributed by GABP. This transcription and 12-16 correspond factor and Spl are considered to be ubiquitous. However, the concentration and phosphorylation-dependent activity of Relative affinity of F promoter fragments for the FTO2B cell or GABP proteins, evaluated by gel shift of the ets probe. Binding reactions contained increased concentrations (10-, 40-, and 100-fold molar excess), indicated by the triangles, of competing oligos D, B, or C (Fig. 1B) or ets, or a 100-fold molar excess of oligo etsmut. Arrows b and c, specific shifts; n.s., nonspecific; F, free probe.
Spl family members vary with cell type and developmental stage (34). Posttranslational modifications of Spl and, possibly, GABP might explain why F-type mRNA expression appears restricted to proliferating cells. Such control could also be exerted by cis-acting sequences located outside the promoter region described here. Moreover, although the four complexes detected between FIO2B proteins and oligo B were ascribed to ets-related proteins, only three were typical of GABP. The minor, faster migrating, complex d could also participate in the activity of the promoter. Finally, the region containing the functional ets motif described here behaved as an enhancer of the M promoter (6) .
In conclusion, we have characterized a third mRNA and its promoter in a gene already known to encode the L and M isozymes of PFK-2/FBPase-2. The organization of the F promoter differs from that of the L-type and M-type promoters, which both contain a TATA box and binding sites for tissue-specific factors and for CCAAT transcription factor/ nuclear factor 1 (6, 20) . The F-type mRNA occurs in proliferating tissues such as preterm placenta, fetal liver and muscle, and established lines of mammalian cells. Our data also suggest that its synthesis is controlled by GABP and, perhaps, other ets-related transcription factors, and by Spl. To our knowledge, only viral genes have been described as GABP targets. Several human tumors are associated with abnormal expression ofets (35). Identification ofcellular genes for which transcription is controlled by ets oncogene products is relevant for our understanding of the malignant phenotype.
